Revenue Update on Aerie Pharmaceuticals Inc(NASDAQ:AERI)

Aerie Pharmaceuticals Inc(NASDAQ:AERI) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Earnings per share were $-0.72. Analysts had estimated an EPS of $-0.74.

In a different note, Cantor Fitzgerald said it Initiates Coverage on Aerie Pharmaceuticals Inc, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Buy’ by the firm.

Aerie Pharmaceuticals Inc (AERI) made into the market gainers list on Fridays trading session with the shares advancing 2.67% or 0.48 points. Due to strong positive momentum, the stock ended at $18.43, which is also near the day’s high of $18.5. The stock began the session at $17.88 and the volume stood at 4,69,356 shares. The 52-week high of the shares is $33.25 and the 52 week low is $10.82. The company has a current market capitalization of $514 M and it has 2,78,92,973 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Apr 26, 2016, Gerald D. Cagle (director) purchased 4,646 shares at $18.24 per share price.Also, On Apr 16, 2015, Anand Mehra (director) sold 425,000 shares at $33.76 per share price.

Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *